Navigate towards Medicamen Organics IPO key dates, price band, GMP, and much more
Medicamen, founded in 1995, boasts over thirty years of expertise in the pharmaceutical manufacturing sector. It specializes in producing various forms of pharmaceutical dosage, including Tablets, Capsules, Oral Liquids, and Ointments. Two plants certified by the WHO-GMP support Medicamen’s operations.
Medicamen has partnerships with numerous local and global entities, including Morepen, Anglo-French, Elder, Bestochem, Shreya Lifesciences, Wipro, Win Medicare, Jagsonpal, Klitch Drugs, Tablet India Limited, Mission Pharma, SH Pharmaceuticals, Knoll, Healing, May & Baker, Emami, and many others, for the production of their products under both contract and loan license agreements.
Medicamen Organics IPO:
Medicamen Organics is preparing to debut its first public offering (IPO) on June 21. The firm intends to secure more than ₹10 crore through this offering and has revealed the price range and additional information regarding the IPO.
Medicamen Organics IPO Price Band:
The range for the initial public offering (IPO) of Medicamen Organics has been established between ₹32 and ₹34 per share. The highest possible price for Medicamen Organics’ IPO is ₹10.54 crore, which includes the issuance of 31 lakh new equity shares.
Medicamen Organics IPO Lot Size:
The initial public offering (IPO) share quantity is 4,000, and the smallest sum needed to invest as a retail investor is ₹136,000.
Medicamen Organics IPO Key Dates:
The Medicamen Organics Initial Public Offering (IPO) is a small to medium-sized enterprise (SME) IPO set to begin accepting investments on Friday, June 21, and will conclude on Tuesday, June 25. The date for distributing shares is June 26, with the official listing date set for June 28. The Medicamen Organics shares will be made available on the NSE SME exchange.
Medicamen Organics IPO Finances:
The firm intends to allocate the funds generated from the issuance of its securities towards covering the costs associated with registering its products in foreign markets, upgrading its facilities, expanding its manufacturing capabilities, covering operational expenses, and other general business needs.
Bal Kishan Gupta serves as the founder of the company. GYR Capital Advisors Pvt Ltd is managing the Medicamen Organics Initial Public Offering (IPO), while Kfin Technologies is handling the registration of the IPO.
Medicamen Organics reported a net profit of ₹95.78 lakh from a total revenue of ₹22.96 crore in the fiscal year 2023. This represents a significant improvement compared to the previous year, where the company recorded a net profit of ₹9.23 lakh and a revenue of ₹21.18 crore.
Over the six-month period ending September 2023, the company achieved a net profit of ₹1.29 crore and generated revenue of ₹11.32 crore.
Medicamen Organics IPO GMP Today:
Medicamen Organics’ General Manufacturing Process (GMP) is currently valued at ₹50 per share, according to analysts following the stock market. This suggests that Medicamen Organics’ shares are being sold at a premium of ₹50 above their original issue price in the unofficial market.
The GMP today shows that Medicamen Organics’ shares are being sold at a significant premium of 147.06%, with a price of ₹84 per share in the unofficial market, compared to their initial public offering (IPO) price of ₹34 per share.
Conclusion
In conclusion, Medicamen Organics, with its robust history and expansive partnerships, is poised to make a significant impact with its IPO. The company’s strategic financial goals and promising performance metrics underscore its potential for growth. The enthusiastic market response, as reflected in the GMP, further highlights investor confidence in Medicamen’s future.
